after first- line platinum-based therapy
Showing 1 - 25 of >10,000
NSCLC Metastatic Trial (bevacizumab plus nab-paclitaxel and platinum)
Not yet recruiting
- Non-small Cell Lung Cancer Metastatic
- bevacizumab plus nab-paclitaxel and platinum
- (no location specified)
Jun 2, 2022
Neuroendocrine Carcinomas Trial in Napoli (Temozolomide)
Completed
- Neuroendocrine Carcinomas
-
Napoli, Campania, ItalyIstituto Tumori di Napoli - Fondazione G. Pascale
Oct 22, 2020
NSCLC Stage IV Trial in Gauting (combination regimen tremelimumab /durvalumab, platinum-based chemo (SoC))
Withdrawn
- NSCLC Stage IV
- combination regimen tremelimumab /durvalumab
- platinum-based chemotherapy (SoC)
-
Gauting, GermanyAsklepios Fachkliniken München-Gauting
Sep 26, 2022
Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)
Not yet recruiting
- Cervical Cancer
- Recombinant humanized anti-PD-1 monoclonal antibody injection
- +4 more
-
Wuhan, Hubei, ChinaTongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023
Small-Cell Lung Cancer Trial in Worldwide (Durvalumab, AZD2811, Carboplatin)
Active, not recruiting
- Small-Cell Lung Cancer
- Durvalumab
- +4 more
-
Grand Rapids, Michigan
- +11 more
Apr 25, 2022
Malignant Pleural Mesothelioma Trial in Edegem, Ghent, Sint-Niklaas (Dendritic cell vaccination, Atezolizumab,
Not yet recruiting
- Malignant Pleural Mesothelioma
- Dendritic cell vaccination
- +2 more
-
Edegem, Antwerp, Belgium
- +2 more
Feb 28, 2023
NSCLC (NSCLC) Trial (Ociperlimab, Placebo, Tislelizumab)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Ociperlimab
- +8 more
- (no location specified)
Mar 17, 2023
Esophageal Squamous Carcinoma, HER-2 Protein Overexpression Trial (RC48+PD-1+platinum-based)
Not yet recruiting
- Esophageal Squamous Carcinoma
- HER-2 Protein Overexpression
- (no location specified)
Sep 24, 2023
Malignant Pleural Mesothelioma Trial in Cairo (Gemcitabine, supportive care)
Not yet recruiting
- Malignant Pleural Mesothelioma
- Gemcitabine
- supportive care
-
Cairo, EgyptAin Shams University Hospital
Dec 20, 2022
Gynecologic Cancer Trial (Experimental product - Fortifit® Powder, Standard of care)
Not yet recruiting
- Gynecologic Cancer
- Experimental product - Fortifit® Powder
- Standard of care
- (no location specified)
Oct 14, 2023
Advanced Lung Squamous Cell Carcinoma Trial in Chengdu (low-dose radiation therapy and stereotactic body radiation therapy,
Not yet recruiting
- Advanced Lung Squamous Cell Carcinoma
- low-dose radiation therapy and stereotactic body radiation therapy
- +2 more
-
Chengdu, Sichuan, ChinaWest China Hospital of Sichuan University
Nov 13, 2023
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib
Not yet recruiting
- Ovarian Cancer
- +4 more
- Fluzoparib Capsules
- Bevacizumab
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Cetntre
Sep 25, 2023
Small Cell Lung Cancer (SCLC) Trial (irinotecan liposome injection)
Unknown status
- Small Cell Lung Cancer (SCLC)
- irinotecan liposome injection
- (no location specified)
Jan 26, 2021
Cervical Cancer Trial in Chongqing, Fuzhou (TQB2868 injection, Paclitaxel injection, Cisplatin injection)
Not yet recruiting
- Cervical Cancer
- TQB2868 injection
- +4 more
-
Chongqing, Chongqing, China
- +1 more
Aug 17, 2023
Toripalimab, First-line Treatment Trial in Guangzhou (EP/EC+PD-1)
Recruiting
- Toripalimab
- First-line Treatment
-
Guangzhou, Guangdong, ChinaSun Yat-sen University cancer center
Mar 7, 2023
Small Cell Lung Cancer Extensive Stage Trial (Pembrolizumab, Plinabulin plus Etoposide and Platinum)
Not yet recruiting
- Small Cell Lung Cancer Extensive Stage
- Pembrolizumab, Plinabulin plus Etoposide and Platinum
- (no location specified)
Feb 15, 2023
Unresectable/Metastatic Colorectal Cancer Trial in Guangzhou (Fruquintinib plus camrelizumab and capecitabine)
Recruiting
- Unresectable/Metastatic Colorectal Cancer
- Fruquintinib plus camrelizumab and capecitabine
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital, Sun Yat-sen University
Nov 19, 2023
Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer Trial (Durvalumab, Monalizumab, Carboplatin or Cisplatin)
Not yet recruiting
- Small Cell Lung Cancer
- +2 more
- Durvalumab
- +3 more
- (no location specified)
Jun 5, 2023
NSCLC Trial in Hangzhou, Nanjing (IBI308, Docetaxel)
Active, not recruiting
- Non-small Cell Lung Cancer
-
Hangzhou, Zhejiang, China
- +1 more
Jun 1, 2021
Advanced Non-squamous Non-Small-Cell Lung Cancer Trial in Jinan (Sintilimab)
Recruiting
- Advanced Non-squamous Non-Small-Cell Lung Cancer
-
Jinan, Shandong, ChinaThe First Affiliated Hospital of Shandong First Medical Universi
Dec 4, 2022
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial (pembrolizumab, paclitaxel)
Completed
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- pembrolizumab
- paclitaxel
- (no location specified)
May 12, 2022
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Beijing (Fluzoparib; Apatinib, Fluzoparib, Placebo)
Active, not recruiting
- Ovarian Cancer
- +2 more
- Fluzoparib; Apatinib
- +2 more
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Apr 22, 2022
Non-Small-Cell Lung Cancer Trial in Jinan (Recombinant human endostatin (Endostar))
Recruiting
- Non-Small-Cell Lung Cancer
- Recombinant human endostatin (Endostar)
-
Jinan, Shandong, ChinaThe First Affiliated Hospital of Shandong First Medical Universi
Oct 8, 2022
Helicobacter Pylori Infection Trial in New Taipei City (Vonoprazan and Amoxicillin, Lansoprazole, Amoxicillin, Clarithromycin
Recruiting
- Helicobacter Pylori Infection
- Vonoprazan and Amoxicillin
- Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole
-
New Taipei City, TaiwanFu Jen Catholic University Hospital, Fu Jen Catholic University
Dec 3, 2023